ERS COPD Research Awards 2007 Sponsored by Boehringer Ingelheim

Boehringer IngelheimThe European Respiratory Society (ERS) is pleased to announce that Dr Morten Dahl, Herlev University Hospital in Copenhagen, Denmark and Simonetta Baraldo, Padova, Italy, are this year's winners of the Society's annual award for research in the field of Chronic Obstructive Pulmonary Disease (COPD).

The ERS COPD Research Award recognises the work of young European ERS members active in pulmonology research and has been awarded for the seventh time this year. It is sponsored by Boehringer Ingelheim and consists of two sponsorships totalling 50,000 Euros to be used for scientific research projects in the field of COPD.

This year, the first prize of 30,000 Euros goes to Morten Dahl for his assessment of risk for COPD in individuals with increased systemic inflammation and less severe alpha-1 antitrypsin deficiency. His research may aid the identification of new biomarkers for COPD and asthma. In his recent research Dr Dahl tested whether increased concentrations of C-reactive protein (CRP) predict future risk of hospitalization and death from COPD in individuals with airway obstruction. The study showed that serum CRP is a strong predictor of future COPD in individuals with airway obstruction.

Dr Dahl completed an MD and a consecutive PhD at the Copenhagen University in Denmark. After an internship at Herlev University Hospital, he received a competitive fellowship from the Danish Medical Research Council that allowed him to join Harvard Medical School, Brigham and the Women's Hospital in Boston as a research fellow.

The second prize of 20,000 Euros was awarded to Simonetta Baraldo for her investigation into the link between excessive inflammatory response and functional abnormalities in asthma and COPD. She is the first author of several recent publications in the area of inflammatory cells in inducing parenchymal destruction and small airway remodelling in COPD. Her most recent work is focussed on the expression of metalloproteinases in patients with COPD at different stages of disease severity to evaluate their role in the clinical progression of the disease.

"On behalf of the ERS I would like to congratulate Morten Dahl and Simonetta Baraldo on their outstanding work and their highly deserved awards," said William MacNee, ERS President. "We would also like to take this opportunity to thank all applicants for the high standard of work submitted. Thanks are also due to Boehringer Ingelheim, a leader in the research and treatment of COPD, for making this award possible," he added. "May I also take this opportunity to remind all our members that the ERS COPD Award is an ongoing initiative. The application for next year's award are open now and we look forward to many submissions from young researchers next year."

European members of the ERS up to age 45 are eligible to apply for the award. The official online application form can be found on the ERS website on www.ersnet.org/copd-award. The deadline for applications is February 21, 2008. Selection of the successful candidates will be made by the Scientific Committee of the ERS.

About The European Respiratory Society
Founded in 1990, the European Respiratory Society (ERS) is a not-for-profit, international medical organisation with more than 7,000 members - scientists, doctors and allied health professionals, coming from over 100 countries. The Society's mission is to alleviate suffering from respiratory disease and to promote lung health through research, knowledge sharing, medical and public education, and working with patient organisations. For more information, visit www.ersnet.org.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information, visit www.boehringer-ingelheim.com.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]